The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH- the State of the Art
Hepatology. 2021 Apr 30. doi: 10.1002/hep.31869. Online ahead of print.
Amreen M Dinani1, Kris V Kowdley2, Mazen Noureddin3
Author information
1Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2Liver Institute Northwest, Seattle, Washington and Elson S. Floyd College of Medicine, Washington State University, WA, USA.
3Division of Digestive and Liver Diseases, Cedar Sinai Medical Center, Los Angeles, CA, USA.
Abstract
The diagnosis of nonalcoholic fatty liver disease and associated fibrosis is challenging given the lack of signs, symptoms and non-existent diagnostic test. Furthermore, follow up and treatment decisions become complicated with a lack of a simple reproducible method to follow these patients longitudinally. Liver biopsy is the current standard to detect, risk stratify and monitor individuals with nonalcoholic fatty liver disease. However, this method is an unrealistic option in a population that affects about one in three to four individuals worldwide. There is an urgency to develop innovative methods to facilitate management at key points in an individual's journey with nonalcoholic fatty liver disease fibrosis. Artificial intelligence is an exciting field that has the potential to achieve this. In this review, we highlight applications of artificial intelligence by leveraging our current knowledge of nonalcoholic fatty liver disease to diagnose and risk stratify NASH phenotypes.